Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for cognitive impairment prevention in brain tumor patients receiving radiotherapy
IRCT20211029052903N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in confusion comparing Memantine with Placebo (2 arms). Primary endpoint: Cognitive impairment. Started Jan 2022; status: completed.
02
Drugs
memantine
03
Conditions
confusion
Beyond the preview
Go deeper on IRCT20211029052903N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211029052903N1.